Targeting TGF-β signal pathways may also be an effective treatment for PAH, considering the upregulation of TGF-β downstream of the loss of function in BMPR2, which has shown a correlation with PH development [130,131]. Here, TGFB1 is linked to pulmonary arterial hypertension.